blue cross blue shield massachusetts glp 1 coverage BCBSM pulling back on GLP-1 Why we are changing coverage

2017;66:A315A315315

Compared with untreated individuals, those receiving GLP-1 therapy showed lower levels of pro-inflammatory cytokines (IL-6, TNF-, IL-12), higher levels of IL-10, reduced expression of endothelial adhesion molecules (ICAM-1, VCAM-1), and decreased leukocyte rolling and adhesion along the vascular endothelium [15]

Since its approval, tens of millions of prescriptions have been written for this and similar medications

When retinopathy is detected, prompt referral to ophthalmology is essential

"Clinical Features Modifying the Cardiovascular Benefits of GLP-1 Receptor Agonists." September 21, 2025

Our board-certified medical team provides customized weight management programs using FDA-approved GLP-1 medications, including semaglutide in Sacramento, CA